Anke Biotechnology’s Human Growth Hormone Injection New Indication Application Accepted
November 27, 2024
Source: drugdu
57
Beijing Business News (Reporter Ding Ning) – On the evening of November 25, Anke Biotechnology (300009) announced that it had received the "Acceptance Notice" administrative licensing document from the National Medical Products Administration. The company’s supplementary application for a new indication of its human growth hormone injection for small for gestational age (SGA) children has been accepted. Anke Biotechnology stated that its human growth hormone injection features no preservatives and is user-friendly. This new indication adds to the eight previously approved indications for the product; if approved, it will help meet the clinical medication needs of such children and enhance the company's market competitiveness.
https://finance.eastmoney.com/a/202411253250010353.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Yingtai Medical acquires Weiqiang Medical December 21, 2024
- 4 innovative medical devices approved for market launch December 21, 2024
- Once a month, potential “best-in-class” lipid-lowering drugs apply for listing December 21, 2024
- Notice! Xinma Pharmaceutical Recruitment and Procurement Involved in Bribery December 21, 2024
- New weight loss drug, the world’s first cAMP-biased GLP-1 agonist has been submitted for marketing December 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
